Disaster at Amarin: Stock plummets 70% after Vascepa patent challenge loss

Amarin's share price tumbled more than 70% in after-market trading Monday to a low of $4 after a Nevada district judge ruled the key patents protecting Vascepa from generic challengers were legally invalid.